virus that infects approximately 90% of the world's adult population.' Whereas primary EBV infection in early life is usually asymptomatic, infection in early adulthood is associated with a self-limiting lymphoproliferative disease, infectious mononucleosis.' Once infected, individuals carry the virus as a life-long infection with persistence of EBV in the lymphoid compartment.' Although the majority of virusinfected individuals remain healthy, EBV is strongly implicated in the pathogenesis of African Burkitt's lymphoma (BL)' and nasopharyngeal carcinoma (NPC).4,5 EBV is also associated with lymphoproliferative disease in immunosuppressed individuals, where it is found in virtually all posttransplant lymphomas and some acquired immunodeficiency syndrome-associated lymphomas, particularly of the central nervous system6
taken some years before the onset of the There is also a threefold increased risk of developing HD after infectious mononucleosis." Recently, more direct evidence linking EBV with HD has been published. Thus, EBV genomes have been detected in tumor material in 19% to 50% of HD cases and in situ hybridization has localized these viral genomes to the malignant HRS cells.""3 The demonstration of monoclonal EBV episomes in HD suggests that clonal cellular proliferation is initiated subsequent to EBV infection." Expression of the small EBV-encoded nonpolyadenylated RNAs EBERl and EBER2 in HRS cells has been reported and is consistent with the finding of these abundant transcripts in all situations where latent EBV infection is ~ustained.'~ An etiological role for EBV in the pathogenesis of HD is further supported by the finding that the oncogenic latent membrane protein 1 (LMP1) viral protein is highly expressed in the malignant HRS cells of EBV-positive HD cases in the absence of EBNA2 e x p r e~s i o n .~~~~" This restricted pattern of EBV latent protein expression is similar to that found in NPC.17, 18 In particular, analysis of EBV transcription in fresh HD biopsy specimens identified EBV nuclear protein 1 (EBNAI) mRNA initiating from the BarnHI F region of the viral genome (so-called F promoter) as in NPC and BL, rather than the Cp and Wp promoters that are used to direct transcription of all the EBNAs in lymphoblastoid cell lines (LCLS).'~-*' EBNAl is consistently expressed in all EBV infections and appears to be essential for viral DNA replication and the maintenance of viral episomes in the infected cell.'' It has been inferred from the RNA data that EBNAl is expressed at the protein level in HD. However, the lack of suitable monoclonal antibody (MoAb) reagents has prevented the direct demonstration of this protein in HRS cells. In this report, we describe the generation of EBNA l-specific MoAbs and their use to detect EBNAl in conventional paraffin tissue sections.
DETECTION OF EBNAI IN HODGKIN'S DISEASE
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coli as a lambda-cro/lacZ-EBNAl-fusion protein was supplied by Bill Sugden (Madison, WI).29 Approximately 20 pg of antigen suspended in phosphate-buffered saline (PBS) was emulsified with complete Freund's adjuvant and injected subcutaneously and intraperitoneally into Lodc rats. Fusion of the myeloma cell line P3X63 Ag 8-653 with the rat immune spleen cells was performed according to the general procedure." Hybridoma supernatants were tested in a solid-phase immunoassay using cell extract derived from SF158 insect cells infected with either recombinant EBNAl-expressing baculovirus or wild-type baculovirus as a control. Extracts were prepared by sonication of infected cells that were suspended in PBS. The cell lysate was cleared by high-speed centrifugation and used to coat polystyrene microtiter plates. Culture supernatants were incubated for 1 hour, and bound rat MoAbs were detected with goatantirat IgG coupled with with horseradish peroxidase, using O-phenylenediamine as substrate. The Ig subclass was determined in a solid-phase enzyme-linked immunosorbent assay (ELISA) with mouse antirat antibodies for capture and biotinylated monoclonal mouse antirat Ig heavy chain-specific antibodies (IgM and IgG subclasses) as indicator^.^'
The antibodies that reacted positively were confirmed by immunofluorescence using SF158 cells infected with the EBNAl-expressing baculovirus and by Western blotting using various EBV-positive and EBV-negative cell lines?6.28 Antibodies that yielded more than one band in the Westem blot or that reacted with proteins in EBVnegative cells were not considered further. Clones designated EBNA1-lH4-1 (IgG2a) and EBNA1-2B4-l (IgG1) were subsequently tested by immunoprecipitation analysis, because they reacted strongly with a variety of EBNAl proteins from different cell lines in the immunoblot. The preparation of cell extract, immunoprecipitation, and subsequent detection of precipitated EBNAl was performed essentially as described earlier. 26 The nonspecific rat IgGl MoAb Rmt6 (E. Kremmer, unpublished) served as a negative control.
Specimens. Tumor samples were obtained as either formalinfixed paraffin wax blocks or frozen tissue from the Queen Elizabeth Hospital (Birmingham, UK) and from the Institute of Pathology (Homburg, Germany). Paraffin wax sections were cut at 5 pm and attached to glass slides by incubation overnight at 60°C. Slides had been pretreated with an adhesive (Frotissuer; The Binding Site, Birmingham, UK). Frozen sections were prepared at 6 pm on a cryostat and then fixed in 4% paraformaldehyde for 20 minutes. Cytospin preparations were made from cell lines and fixed in 4% paraformaldehyde for 20 minutes before immunostaining. Selected lines were pelleted, processed to paraffin wax, and sectioned as described above. In addition, B95-8 LCLs and Louckes lines were used to generate tumors in SCID mice as previously described." Tumors obtained in this way were either snap-frozen or processed to paraffin wax.
Immunofluorescent staining. Cell cytospin preparations or frozen tissue sections were fixed as described above and either directly analyzed or pretreated in 0.1 molL citrate buffer, pH 6.0, for 50 minutes in a microwave oven. The slides were then incubated with MoAbs 1H4-1 or 2B4-1 diluted 1 5 0 or 1: 100 in PBS containing 20% normal rabbit serum; the PBS/2O% normal rabbit serum solution was used for all subsequent dilutions. After a 2 hours of incubation at 37°C the slides were washed in PBS and then incubated with a 1 5 0 dilution of fluorescein isothiocyanate (FlTC)-conjugated goat antirat Ig (Sigma St Louis, MO) for 1 hour at 37°C. At this stage the slides were either (1) washed in DABCO solution (W% glycerol, 10% PBS, and 2.5% W/V 1.4-diazabicyclo (2,2,2)octane, pH 8.6) and viewed under a UV-fluorescence microscope or (2) treated to a second round of staining using a 150 dilution of fluorescein isothiocyanateconjugated rabbit antigoat Ig (Sigma) before mounting and viewing.
Immunohistology. Initially, specimens were analyzed for the presence of latent EBV infection by in situ hybridization using digoxigenin-labeled riboprobes to detect the EBERl and EBER2 transcripts according to published procedure^.^^.'^ The presence of latent EBV infection was confirmed on selected cases by immunohistochemistry for LMPl using the CS1-4 MoAb as described prev i o~s l y .~~ Immunohistochemistry for EBNAl was then performed on each specimen. Briefly, paraffin sections were deparaffinized and pretreated in 0.1 mol/L citrate buffer, pH 6.0, for 50 minutes in a microwave oven. Endogenous peroxidase activity was blocked in 0.3% hydrogen peroxide in methanol. After a brief wash in Trisbuffered saline pH 7.6, tissue sections were incubated in MoAbs IH4-1 and 2B4-1 for 1 hour at dilutions of 1: 100 and 1:200, respectively. All antibodies were diluted in 10% normal sheep serum. Bound antibody was detected using rabbit antirat Igs (catalogue no. 2455; Dako Ltd, Glostrop, Denmark) at a dilution of 1:400, followed by biotinylated goat antirabbit (catalogue no. W32; Dako) at 1: 100. Finally, the streptavidin ABC complex was applied (catalogue no. K492; Dako). Peroxidase activity was visualized by the standard diaminobenzidine reaction. Frozen sections were transferred directly to the citrate buffer step, and the immunostaining performed in the same way as for paraffin sections.
RESULTS
Biochemical characterization of MoAbs against EBNAI.
MoAbs were generated using a bacterially expressed EBNAl-lambda-cro/lacZ fusion protein that is devoid of the "Gly-Gly-Ala" repeats of EBNA1.29 MoAbs positive for EBNAl reactivity in the solid-phase immunoassay were subsequently assayed by Western blot analysis for their ability to detect EBNAl from a variety of cell lines. Clones that recognized additional (nonspecific) bands were not considered further. Clones designated EBNA 1 -1 H4-1 (rat IgG2a) and EBNAl-2B4-1 (rat IgG1) were subcloned and analyzed in greater detail; these clones will subsequently be referred to as 1H4 and 2B4. A representative Western blot analysis using clone 1H4 is shown in Fig 1A. The right panel in Fig  1A shows the staining of EBNAl expressed in baculovirusinfected insect cells; no signal was obtained with cell extracts derived from EBNA2A-expressing cells or cells infected with the wild-type (W) baculovirus. In cell extracts from EBV-positive lymphoid cell lines, the 1H4 MoAb detected a single band corresponding to EBNA1, as verified by the different strain-specific electrophoretic mobilities of EBNAl which are mainly because of differences in the length of the "Gly-Gly-Ala" repeats. The antibodies detected EBNAl derived from a variety of LCL and BL cell lines and recognized EBNAl from both type 1 and type 2 EBV isolates. It was noted that the EBNA2-deficient P3HR-1 cells expressed an increased amount of EBNAl as compared with the parental, EBNA2B-expressing cell line Jijoye. The EBV-negative cell lines B U l and BJAB did not yield a detectable signal.
Both 1H4 and 2B4 were also tested in immunoprecipitation analysis using extracts from different EBV-positive and EBV-negative cell lines. The result of an experiment using extracts of the EBV-positive B95.8 cell line and the EBVnegative BJAB cell line is shown in Fig 1B. 1H4 precipitated EBNAl from the B958 extract, whereas, as expected, no signal was obtained with the BJAB cell extract cell line or with the irrelevant rat MoAb Rmt6. Both 1H4 and 2B4 de- tected the EBNAI protein only in a subset of cell lines by immunoprecipitation, reacting most strongly with the B95-8 EBNAl used for immunization but also precipitating EBNA I derived from the Raji or Jijoye BL lines. In immunofluorescence analysis, 1H4 and 2B4 yielded a clear signal in insect cells infected with EBNAI -expressing baculovirus, whereas almost no signal was obtained using EBV-positive B-lymphoid cell lines (data not shown). However, microwave treatment and the use of a second round of immunofluorescent staining resulted in the detection of EBNAI in GRASSER ET AL both LCL and EBV-positive BL cell lines. Taken together, these data indicated that the antibodies reacted primarily with an epitope that became fully available only after denaturation. (Mutu c148, c62 ) BL cell lines were tested. EBV-negative cell lines tested included BJAB, BL2, Ramos, and the EBV-negative Hodgkin's line KMH2. Whereas the EBV-negative cell lines tested showed no reactivity with the MoAbs, strong nuclear staining with a pronounced granular appearance was observed for both IH4 and 2B4 in all the EBV-positive lines tested (Fig 2A through D) . This was observed in both cytospin preparations and paraffin wax sections of cell lines. No qualitative nor quantitative difference in the expression pattern between type I and type Ill BL cells was observed. Paraffin wax sections of B95-8 LCLderived SCID tumors also showed strong labeling of tumor cells with both antibodies, whereas the EBV-negative Louckes-derived SCID tumors were not labeled.
Immunohistochemical detection of EBNAI in clinical
specimens. Finally, we analyzed paraffin wax sections from a series of EBV-associated lymphoid tumors. Of 31 EBER-positive HD specimens, 20 showed detectable expression of EBNAI within HRS cells using the 2B4 MoAb, whereas 1 1 cases were positive with the 1 H4 MoAb (Fig 2E  and F) . With one exception, all IH4-positive cases were also 2B4-positive. However, in those cases in which EBNAI could be detected, there was always a fraction of tumor cells that were not labeled. A total of 2 1 EBER-negative HD cases showed no labeling of HRS cells with either antibody. These negative cases were mostly of nodular sclerosis subtype ( I6 cases). In positive cases, the HRS cells showed a granular staining pattern that was similar to that observed in the cell lines, although in some cells the periphery of the nucleus was also strongly labeled. However, in general, the staining was weaker than that observed in the cell lines. The 2B4 antibody also appeared to react weakly with a subset of nonmalignant cells that included endothelial cells. This nonspecific nuclear staining was readily distinguished from that observed in tumor cells. In EBER-positive cases, there was no relationship between EBNAI expression and subtype of HD ( Table 1) . The immunohistological analysis was also extended to cryostat sections of HD. Of 9 EBER-positive specimens, 3 showed labeling of tumor cells with the 1H4 reagent, whereas 7 cases were positive with the 2B4 MoAb. The pattern of staining was identical to that observed in paraffin sections (data not shown). A total of 4 EBER-negative cases examined showed no labeling in tumor cells. Paraffin wax sections of BL and human immunodeficiency virus (H1V)-associated intracerebral B-cell lymphoma were also tested.." All 3 EBER-positive BL specimens and 8 of 8 HIVassociated lymphomas showed labeling of tumor cells with both MoAbs. Once again, the characteristic granular staining For personal use only. on September 24, 2017. by guest www.bloodjournal.org From pattern was observed within tumor cells, but in most cases, the signals were much stronger than those observed in the tumor cells of HD (data not shown). A single EBER-positive T-cell lymphoma studied also showed labeling with both antibodies (data not shown). EBNAl could not be detected in 8 EBER-negative large cell anaplastic lymphomas tested.
DISCUSSION
In this report, we describe the production and characterization of rat MoAbs directed against EBNA1. Two MoAb while failing to reliably stain cells in immunofluorescence analysis suggests that the MoAbs recognize an epitope that is partially masked in the native protein but is exposed on denaturation.
Previous reports have shown that a proportion of HD cases contain EBV genomes and the EBV-encoded EBERs in the malignant HRS ~ells.~'-I~ Subsequently, the consistent expression of LMPl in the HRS cells of EBV-positive HD was shown in the absence of EBNA2 expression.".I6 We recently analyzed EBV transcription in HD using reverse transcription polymerase chain reaction analysis and confirmed that the transcriptional program in HRS cells is similar to that observed in NPC." Of particular interest was the detection of selective EBNAI expression from the FP promoter that is also used to drive EBNAl transcription in NPC biopsy specimens and BL cell lines which retain the original BL biopsy phenotype.zO~'l Although this data strongly suggested that the EBV genome maintenance protein EBNAl is expressed in HD, the paucity of HRS cells in HD biopsy specimens precluded direct demonstration of EBNAl protein using the standard anticomplement immunofluorescence assay." This assay is notoriously prone to nonspecific cross-reactivities when applied to tumors and, because it is based on the use of selected EBNA-positive human sera and complement, is particularly problematic when used to analyze lymphoid malignancies. Furthermore, the presence of antibodies against the other EBNA proteins and lytic virus antigens in human serum can confound the interpretation of anticomplement immunofluorescence staining.
Thus, the aim of the present study was to develop MoAbs against EBNAl and to show that EBV-positive HD, in particular, but also BL and HIV-associated B-cell lymphomas express EBNA1. The MoAbs were used to stain smears of B-cell lines or tissue sections of HD, BL, and HIV-associated cerebral B-cell lymphoma. The presence of EBNAl could be shown in LCLs and BL cell lines using immunofluorescence or immunohistochemistry subsequent to paraformaldehyde fixation and microwave treatment of the smears. Similar treatment of paraffin-embedded or cryostat sections of HD, BL, and HIV-associated intracranial B lymphoma clearly showed the granular staining pattern characteristic of EBNAl reactivity. To our knowledge, this is the first direct demonstration the EBNAl protein in tissue sections of these tumors.
In the established cell lines, most cells expressed detectable amounts of EBNA1, whereas in tissue sections variable numbers of tumor cells reacted with the EBNAI-specific MoAbs. It is possible that antigen availability and preservation may affect the detectability of EBNAl and that this effect is not evident in tumors with a homogeneous population of EBV-positive cells. This explanation is supported by the observation that those tumors with the most intense EBNAl staining tended to be those with the greatest number of EBNAl-positive cells. Furthermore, when extremely high levels of EBNAl were expressed in the baculovirus system, the MoAbs were readily able to detect the protein without the need for microwave treatment. This suggests that the level of EBNAl expression affects the detectability of the protein. Nevertheless, BL and HIV-associated B-cell lymphoma cells contained readily detectable amounts of protein, whereas HRS cells appeared to express only moderate or very low levels of EBNA1, and some cases of EBERpositive HD were negative for EBNA1. That this inability to consistently detect EBNAl in EBV-positive HD is not caused by different subtypes of EBV or different transcriptional programs is evidenced by the ability to detect EBNA 1 by Western blot analysis in all EBV-positive cell lines analyzed, including those carrying different EBV strains (ie, type 1 versus type 2 isolates)3R and BL cell lines expressing EBNAl from the FP promoter (ie, group I versus group III)." Our overall conclusion is that, in a proportion of EBVpositive HD cases, a combination of low-level expression of EBNAl and the problems of antigen preservation in paraffinembedded material hampered the reliable detection of EBNAl using immunohistochemistry.
The expression of EBNAl in all forms of EBV latency is consistent with the essential role of this protein in viral DNA replication and maintenance of the viral episome.22 Studies in which specific antisense inhibition of EBNAl resulted in the growth inhibition of a BL cell line emphasize the importance of EBNAl in the development of BL.3y Other data provide strong evidence that EBNA1 can participate in the deregulation of c-myf in the presence of a myc/Ig translocation through activation of the Ig enhancer." Although this effect suggests an additional role for EBNAl in the pathogenesis of BL, the transactivation of certain promoters by EBNAl may also be relevant to the development of HD and other EBV-associated malignancies. Consistent with this hypothesis is recent data showing that transgenic mice expressing EBNAl from Ig heavy chain enhancer develop Iyrnph~ma.~" To date, every one of the EBV-latent proteins except EBNAl has been shown to be a potential target for EBV-specific cytotoxic T l y m p h o~y t e s .~~.~~ Therefore, it is tempting to speculate that the inability of EBNAl to serve as a cytotoxic T lymphocyte target may facilitate its role in both the persistence and pathologic role of EBV. Although the site of EBV persistence in vivo remains unknown, on the basis of current evidence, it has been proposed that the B-lymphoid compartment is responsible for the maintenance of chronic EBV infection. ' The availability of MoAbs
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From against EBNAl that can be used in immunohistology will not only advance our understanding of the role of EBV in the various virus-associated tumors but will also be important in identifying the cell types and sites mediating EBV persistence.
